In vitro pharmacodynamic studies of activities of ketolides HMR 3647 (Telithromycin) and HMR 3004 against extracellular or intracellular Helicobacter pylori - PubMed (original) (raw)

In vitro pharmacodynamic studies of activities of ketolides HMR 3647 (Telithromycin) and HMR 3004 against extracellular or intracellular Helicobacter pylori

I Gustafsson et al. Antimicrob Agents Chemother. 2001 Jan.

Abstract

The pharmacodynamic properties of the ketolides HMR 3647 (telithromycin) and HMR 3004 were studied against Helicobacter pylori. Both ketolides showed a pronounced concentration-dependent killing, a significant postantibiotic effect, a long postantibiotic sub-MIC effect, and a reduction of intracellular H. pylori.

PubMed Disclaimer

Figures

FIG. 1

Concentration-dependent killing with HMR 3647. Bars indicate standard deviations.

FIG. 2

(a) Concentration curve for HMR 3004. Bars indicate standard deviations. (b) Intracellular H. pylori exposed to 10 times the MIC of HMR 3647. Bars indicate standard deviations.

Cited by

A long-distance rRNA base pair impacts the ability of macrolide antibiotics to kill bacteria.
Svetlov MS, Cohen S, Alsuhebany N, Vázquez-Laslop N, Mankin AS. Svetlov MS, et al. Proc Natl Acad Sci U S A. 2020 Jan 28;117(4):1971-1975. doi: 10.1073/pnas.1918948117. Epub 2020 Jan 13. Proc Natl Acad Sci U S A. 2020. PMID: 31932436 Free PMC article.
Antibiotics for treatment of resistant gram-positive coccal infections.
Al-Tatari H, Abdel-Haq N, Chearskul P, Asmar B. Al-Tatari H, et al. Indian J Pediatr. 2006 Apr;73(4):323-34. doi: 10.1007/BF02825827. Indian J Pediatr. 2006. PMID: 16816494 Review.
The ketolides: a critical review.
Zhanel GG, Walters M, Noreddin A, Vercaigne LM, Wierzbowski A, Embil JM, Gin AS, Douthwaite S, Hoban DJ. Zhanel GG, et al. Drugs. 2002;62(12):1771-804. doi: 10.2165/00003495-200262120-00006. Drugs. 2002. PMID: 12149046 Review.
Sulforaphane inhibits extracellular, intracellular, and antibiotic-resistant strains of Helicobacter pylori and prevents benzo[a]pyrene-induced stomach tumors.
Fahey JW, Haristoy X, Dolan PM, Kensler TW, Scholtus I, Stephenson KK, Talalay P, Lozniewski A. Fahey JW, et al. Proc Natl Acad Sci U S A. 2002 May 28;99(11):7610-5. doi: 10.1073/pnas.112203099. Proc Natl Acad Sci U S A. 2002. PMID: 12032331 Free PMC article.

References

1. Boswell F J, Andrews J M, Wise R. Pharmacodynamic properties of HMR 3647, a new ketolide, on respiratory pathogens, enterococci and Bacteroides fragilis demonstrated by studies of time-kill kinetics and postantibiotic effect. J Antimicrob Chemother. 1998;41:149–153. - PubMed
1. Craig W A. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis. 1998;26:1–12. - PubMed
1. Enroth H, Wreiber K, Rigo R, Risberg D, Uribe A, Engstrand L. In vitro aging of Helicobacter pylori: changes in morphology, intracellular composition and surface properties. Helicobacter. 1999;4:7–16. - PubMed
1. Evans D G, Evans D J, Jr, Graham D Y. Adherence and internalization of Helicobacter pylori by HEp-2 cells. Gastroenterology. 1992;102:1557–1567. - PubMed
1. Glupczynski Y, Burette A, Lamy V, Garrino M G. Evolution of H. pylori primary resistance to antimicrobial agents in Belgium between 1995 and 1998. Gut. 1998;43(Suppl. 2):A48.

In vitro pharmacodynamic studies of activities of ketolides HMR 3647 (Telithromycin) and HMR 3004 against extracellular or intracellular Helicobacter pylori - PubMed (original) (raw)